Geneva, Switzerland (PRWEB) April 23, 2013
Geneva, Switzerland - April 23, 2013 – Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today the Company’s vice present of business development, Andrew Sandford, will be speaking on The Selexis SURE CHO-Mplus™ Libraries: Next Generation Innovation for Addressing Difficult-to-Express Proteins at the 2013 PEGS Summit on Wednesday, May 1, 2013 at the Seaport World Trade Center in Boston, Massachusetts. Selexis will also be exhibiting at the conference, April 29 – May 3, 2013.
Andrew Sandford’s lecture is part of the Engineering Antibodies track. Conference attendees can hear Mr. Sandford’s lecture on Wednesday, May 1 at 3:05 PM.
Tackling production bottlenecks with difficult-to-express (DTE) proteins can significantly delay development programs. The SURE CHO-Mplus™ Libraries, the newest innovation from the SUREtechnology Platform™, consists of proprietary libraries specifically designed to address a range of production bottlenecks, including metabolic limitations, trafficking backlogs, improper folding and altered post-translational modifications. The libraries allow for parallel experimentation to overcome DTE protein development issues in a shorter timeframe.
Additionally, conference attendees can meet Selexis representatives at Booth 321, April 29 – May 3. To schedule meetings in advance, please contact Selexis at SURE@selexis.com.
Registration for the PEGS conference is required. For more information, visit http://www.pegsummit.com/
About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company’s SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated over 1,700 cell lines being used in a variety of programs from drug discovery to late-stage clinical trials.
For more information:
Read the full story at http://www.prweb.com/releases/PEGS_protein_summit/selexis_antibody/prweb10660553.htm.
Copyright©2012 Vocus, Inc.
All rights reserved